SAB Biotherapeutics (SABS) Competitors

SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

Which has better valuation & earnings, SABS or FBIO?

SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$2.24M	6.34	-$42.19M	N/A	N/A
Fortress Biotech	$62.50M	0.76	-$60.64M	-$3.05	-0.57

Is SABS or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to SAB Biotherapeutics' net margin of -1,450.14%. Fortress Biotech's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
Fortress Biotech	-84.53%	N/A	-34.93%

Do analysts rate SABS or FBIO?

SAB Biotherapeutics currently has a consensus target price of $12.40, indicating a potential upside of 705.19%. Fortress Biotech has a consensus target price of $21.00, indicating a potential upside of 1,113.87%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer SABS or FBIO?

Fortress Biotech received 299 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 82.86% of users gave SAB Biotherapeutics an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
SAB Biotherapeutics	Outperform Votes 29 82.86%	Underperform Votes 6 17.14%
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%

Do institutionals & insiders hold more shares of SABS or FBIO?

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media prefer SABS or FBIO?

In the previous week, Fortress Biotech had 4 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 6 mentions for Fortress Biotech and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.93 beat Fortress Biotech's score of 0.51 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, SABS or FBIO?

SAB Biotherapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Summary

Fortress Biotech beats SAB Biotherapeutics on 10 of the 15 factors compared between the two stocks.